Appropriate administration schedule of D-penicillamine for pediatric Wilson's disease patients based on urinary copper excretion

被引:2
|
作者
Fukuoka, N [1 ]
Morita, S
Hamatani, S
Okada, H
Kondoh, M
Imai, T
Ohnishi, S
Itoh, S
机构
[1] Kagawa Med Univ, Dept Hosp Pharm, Kagawa, Japan
[2] Kagawa Med Univ, Dept Pediat, Kagawa, Japan
关键词
Wilson's disease; D-penicillamine; urinary copper excretion; administration schedule;
D O I
10.1248/yakushi.122.585
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this study was to increase the amount of copper excreted resulting from the administration of D-penicillamine (DP) in pediatric Wilson's disease (WD) patients. By measuring the urinary copper excretion after adjusting the administration schedules, the appropriate timing for DP administration was investigated. The subjects were three brothers with pediatric WD. The initial daily dose of DP was 5 mg/kg/day, and gradually increased to the maintenance dose of 20 mg/kg/day. Until the maintenance daily dose was reached, DP was administered 2 h after the morning and evening meal. After reaching the maintenance daily dose of DP, the appropriate timing for taking DP was investigated in both the morning and evening. Three schedules of DP administration were compared: 2 h after meals; 30 min before meals (with fasting); and 1 h before the morning and 1.5 before the evening meal (direction 1). The resulting urinary copper excretion on each dosing schedule was compared. Little difference was found in urinary copper excretion on the first two schedules, i.e., 2 h after meals and 30 min before meals. When DP was administered 30 min before meals, urinary copper excretion [mug/day] was 1173 in the first brother, 918 in the second, and 875 in the third. When DP was administered according to direction 1, however, urinary copper excretion was increased significantly to 1701 in the first brother, 2701 in the second, and 3808 in the third. It is known that the efficiency of urinary copper excretion with DP administration depends on the maintenance of chelating ability after absorption from the gastrointestinal tract. Our results indicate that the excretion was lower when DP was administered 2 h after or 30 min before meals (with fasting), as recommended in the package insert. Thus to achieve better copper excretion efficiency, direction 1 is recommended for WD patients.
引用
收藏
页码:585 / 588
页数:4
相关论文
共 50 条
  • [41] D-PENICILLAMINE DOES NOT INCREASE URINARY BISMUTH EXCRETION IN PATIENTS TREATED WITH TRIPOTASSIUM DICITRATO BISMUTHATE
    NWOKOLO, CU
    POUNDER, RE
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (04) : 648 - 650
  • [42] D-penicillamine-induced ANA (+) ANCA (+) vasculitis in pediatric patients with Wilson's disease
    Lee, Yeonhee
    Lee, Sang Taek
    Cho, Heeyeon
    CLINICAL NEPHROLOGY, 2016, 85 (05) : 296 - 300
  • [43] Chemosensitivity of U251 Cells to the Co-treatment of D-Penicillamine and Copper: Possible Implications on Wilson Disease Patients
    Katerji, Meghri
    Barada, Kassem
    Jomaa, Mustapha
    Kobeissy, Firas
    Makkawi, Ahmad-Kareem
    Abou-Kheir, Wassim
    Usta, Julnar
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2017, 10
  • [44] Gut Akkermansia enhances liver protection and facilitates copper removal during D-penicillamine treatment in a Wilson's disease model
    Huang, Xi
    Jin, Yanqi
    Wang, Tianyuan
    Fu, Danting
    Ma, Jindi
    Yu, Xiaopeng
    Lu, Yingfeng
    Song, Jingyuan
    Chen, Yu
    Yan, Ren
    Zhang, Yimin
    MICROBIOLOGY SPECTRUM, 2025,
  • [45] Epileptic status immediately after initiation of D-penicillamine therapy in a patient with Wilson's disease
    Berger, Benjamin
    Mader, Irina
    Damjanovic, Kornelija
    Niesen, Wolf-Dirk
    Stich, Oliver
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2014, 127 : 122 - 124
  • [46] D-penicillamine induced lupus erythematosus - the complication of Wilson's disease treatment - a case report
    Antos, A.
    Litwin, T.
    Przybylkowski, A.
    Nska, M. Skowro
    Kurkowska-Jastrzebska, I.
    Czlonkowska, A.
    MOVEMENT DISORDERS, 2021, 36 : S508 - S508
  • [47] Effects of long-term treatment in Wilson's disease with D-penicillamine and zinc sulphate
    Czlonkowska, A
    Gajda, J
    Rodo, M
    JOURNAL OF NEUROLOGY, 1996, 243 (03) : 269 - 273
  • [48] D-penicillamine induced myasthenia gravis - the possible complication of Wilson's disease treatment.
    Antos, A.
    Litwin, T.
    Bembenek, J.
    Skowronska, M.
    Kurkowska-Jastrzebska, I.
    Czlonkowska, A.
    MOVEMENT DISORDERS, 2023, 38 : S507 - S508
  • [49] Early onset of nephrotic syndrome after treatment with D-penicillamine in a patient with Wilson's disease
    Siafakas, CG
    Jonas, MM
    Alexander, S
    Herrin, J
    Furuta, GT
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 1998, 93 (12): : 2544 - 2546
  • [50] Wilson's disease: long-term follow-up of a cohort of 24 patients treated with D-penicillamine
    Lowette, Klaartje F.
    Desmet, Koen
    Witters, Peter
    Laleman, Wim
    Verslype, Chris
    Nevens, Frederik
    Fevery, Johan
    Cassiman, David M.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2010, 22 (05) : 564 - 571